176 related articles for article (PubMed ID: 20198621)
1. Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer.
Nagano T; Yasunaga M; Goto K; Kenmotsu H; Koga Y; Kuroda J; Nishimura Y; Sugino T; Nishiwaki Y; Matsumura Y
Int J Cancer; 2010 Dec; 127(11):2699-706. PubMed ID: 20198621
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment.
Nagano T; Yasunaga M; Goto K; Kenmotsu H; Koga Y; Kuroda J; Nishimura Y; Sugino T; Nishiwaki Y; Matsumura Y
Clin Cancer Res; 2009 Jul; 15(13):4348-55. PubMed ID: 19509138
[TBL] [Abstract][Full Text] [Related]
3. The antitumor activity of NK012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts.
Kenmotsu H; Yasunaga M; Goto K; Nagano T; Kuroda J; Koga Y; Takahashi A; Nishiwaki Y; Matsumura Y
Cancer; 2010 Oct; 116(19):4597-604. PubMed ID: 20572031
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
Nakajima TE; Yasunaga M; Kano Y; Koizumi F; Kato K; Hamaguchi T; Yamada Y; Shirao K; Shimada Y; Matsumura Y
Int J Cancer; 2008 May; 122(9):2148-53. PubMed ID: 18196580
[TBL] [Abstract][Full Text] [Related]
5. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors.
Koizumi F; Kitagawa M; Negishi T; Onda T; Matsumoto S; Hamaguchi T; Matsumura Y
Cancer Res; 2006 Oct; 66(20):10048-56. PubMed ID: 17047068
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.
Kuroda J; Kuratsu J; Yasunaga M; Koga Y; Kenmotsu H; Sugino T; Matsumura Y
Clin Cancer Res; 2010 Jan; 16(2):521-9. PubMed ID: 20068081
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic enhancement of S-1 with CPT-11 through down-regulation of thymidylate synthase in bladder cancer.
Ide H; Kikuchi E; Hasegawa M; Hattori S; Yasumizu Y; Miyajima A; Oya M
Cancer Med; 2013 Aug; 2(4):488-95. PubMed ID: 24156021
[TBL] [Abstract][Full Text] [Related]
8. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
9. Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma.
Kuroda J; Kuratsu J; Yasunaga M; Koga Y; Saito Y; Matsumura Y
Int J Cancer; 2009 Jun; 124(11):2505-11. PubMed ID: 19189401
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan.
Nakajima TE; Yanagihara K; Takigahira M; Yasunaga M; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Mihara K; Ochiya T; Matsumura Y
Cancer Res; 2008 Nov; 68(22):9318-22. PubMed ID: 19010905
[TBL] [Abstract][Full Text] [Related]
11. Detailed distribution of NK012, an SN-38-incorporating micelle, in the liver and its potent antitumor effects in mice bearing liver metastases.
Takahashi A; Ohkohchi N; Yasunaga M; Kuroda J; Koga Y; Kenmotsu H; Kinoshita T; Matsumura Y
Clin Cancer Res; 2010 Oct; 16(19):4822-31. PubMed ID: 20807756
[TBL] [Abstract][Full Text] [Related]
12. Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression.
Sumitomo M; Koizumi F; Asano T; Horiguchi A; Ito K; Asano T; Kakizoe T; Hayakawa M; Matsumura Y
Cancer Res; 2008 Mar; 68(6):1631-5. PubMed ID: 18339841
[TBL] [Abstract][Full Text] [Related]
13. Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
Sakurai Y; Yoshida I; Kamoshida S; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Ann Surg Oncol; 2008 Aug; 15(8):2301-9. PubMed ID: 18506536
[TBL] [Abstract][Full Text] [Related]
14. Antitumour activity of NK012, SN-38-incorporating polymeric micelles, in hypovascular orthotopic pancreatic tumour.
Saito Y; Yasunaga M; Kuroda J; Koga Y; Matsumura Y
Eur J Cancer; 2010 Feb; 46(3):650-8. PubMed ID: 20015633
[TBL] [Abstract][Full Text] [Related]
15. Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer.
Takeda M; Okamoto I; Hirabayashi N; Kitano M; Nakagawa K
Lung Cancer; 2011 Jul; 73(1):103-9. PubMed ID: 21111509
[TBL] [Abstract][Full Text] [Related]
16. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
17. Schedule-dependent synergism of vinorelbine and 5-fluorouracil/UFT against non-small cell lung cancer.
Matsumoto S; Igishi T; Hashimoto K; Kodani M; Shigeoka Y; Nakanishi H; Touge H; Kurai J; Makino H; Takeda K; Yasuda K; Hitsuda Y; Shimizu E
Int J Oncol; 2004 Nov; 25(5):1311-8. PubMed ID: 15492820
[TBL] [Abstract][Full Text] [Related]
18. Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
Takechi T; Okabe H; Ikeda K; Fujioka A; Nakagawa F; Ohshimo H; Kitazato K; Fukushima M
Oncol Rep; 2005 Jul; 14(1):33-9. PubMed ID: 15944764
[TBL] [Abstract][Full Text] [Related]
19. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
[TBL] [Abstract][Full Text] [Related]
20. Low-dose docetaxel enhances the sensitivity of S-1 in a xenograft model of human castration resistant prostate cancer.
Hasegawa M; Miyajima A; Kosaka T; Yasumizu Y; Tanaka N; Maeda T; Shirotake S; Ide H; Kikuchi E; Oya M
Int J Cancer; 2012 Jan; 130(2):431-42. PubMed ID: 21351099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
